PDI (NASDAQ:PDII) is undervalued as higher investment spending results in temporary margin compression. However, a low EBITDA multiple and high net cash balance (69% of the market cap) provide downside protection while early evidence of a successful business transition should encourage investors that management is on the right track.
PDII provides outsourced commercial services to pharmaceutical, biotech and healthcare companies in the U.S. The three operating segments include:
Sales services. This segment consists of the outsourced sales teams and EngageCE unit, which focuses on instilling best-practice treatment standards and procedures among healthcare practitioners.
Marketing services. This segment consists of the Group DCA and Voice units. Group DCA (acquired in November 2010) provides...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|